Colchicine for secondary prevention in coronary disease.

The article discusses that according to Canakinumab Anti-inflammatory Thrombosis Outcome Study, implementing anti-inflammatory treatment with anti-inflammatory drug colchicine to patients with coronary disease have clinical benefit as the cardiac patients have life-long risk of cardiovascular death, myocardial infarction and ischemic stroke.